| . | . | Pre-COVID (N = 107) . | During-COVID (N = 104) . | P-value . |
|---|---|---|---|---|
| Fecal calprotectinb | Overall | 867.1 (682.8) | 1653.5 (1677.4) | .001* |
| - Crohns | 650.5 (507.3) | 1692.5 (1854.7) | .003* | |
| - UC | 1153.9 (847.9) | 1691.8 (1338.4) | .09 | |
| - IC | 1214.7 (17.4) | 882.0 (18.4) | .001* | |
| - VEO-IBD | 1055.3 (867.7) | 1447.8 (1417.8) | .35 | |
| Hemoglobinb | Overall | 11.5 (1.8) | 11.1 (2.3) | .13 |
| - Crohns | 11.5 (1.5) | 11.1 (2.4) | .15 | |
| - UC | 11.5 (2.2) | 11.3 (2.3) | .37 | |
| - IC | 11.8 (2.7) | 10.8 (1.7) | .29 | |
| - VEO-IBD | 10.4 (0.9) | 11.1 (1.4) | .20 | |
| Albuminb | Overall | 3.5 (0.8) | 3.3 (0.8) | .08 |
| - Crohns | 3.4 (0.7) | 3.1 (0.9) | .06 | |
| - UC | 3.5 (0.9) | 3.6 (0.7) | .31 | |
| - IC | 3.8 (0.9) | 3.6 (0.5) | .39 | |
| - VEO-IBD | 4.4 (0.4) | 3.8 (0.6) | .05* | |
| CRPb | Overall | 32.6 (40.8) | 44.0 (96.2) | .16 |
| - Crohns | 41.2 (44.1) | 55.3 (113.8) | .21 | |
| - UC | 30.4 (55.9) | 22.9 (38.7) | .30 | |
| - IC | 17.7 (27.9) | 29.2 (36.0) | .32 | |
| - VEO-IBD | 3.7 (4.1) | 5.4 (4.1) | .29 | |
| ESRb | Overall | 37.2 (28.9) | 36.0 (32.0) | .40 |
| - Crohn’s | 41.8 (30.6) | 39.2 (32.4) | .33 | |
| - UC | 32.3 (25.0) | 32.4 (34.4) | .50 | |
| - IC | 35.3 (41.2) | 23.0 (4.0) | .32 | |
| - VEO-IBD | 18.3 (8.3) | 17.8 (16.1) | .48 |
| . | . | Pre-COVID (N = 107) . | During-COVID (N = 104) . | P-value . |
|---|---|---|---|---|
| Fecal calprotectinb | Overall | 867.1 (682.8) | 1653.5 (1677.4) | .001* |
| - Crohns | 650.5 (507.3) | 1692.5 (1854.7) | .003* | |
| - UC | 1153.9 (847.9) | 1691.8 (1338.4) | .09 | |
| - IC | 1214.7 (17.4) | 882.0 (18.4) | .001* | |
| - VEO-IBD | 1055.3 (867.7) | 1447.8 (1417.8) | .35 | |
| Hemoglobinb | Overall | 11.5 (1.8) | 11.1 (2.3) | .13 |
| - Crohns | 11.5 (1.5) | 11.1 (2.4) | .15 | |
| - UC | 11.5 (2.2) | 11.3 (2.3) | .37 | |
| - IC | 11.8 (2.7) | 10.8 (1.7) | .29 | |
| - VEO-IBD | 10.4 (0.9) | 11.1 (1.4) | .20 | |
| Albuminb | Overall | 3.5 (0.8) | 3.3 (0.8) | .08 |
| - Crohns | 3.4 (0.7) | 3.1 (0.9) | .06 | |
| - UC | 3.5 (0.9) | 3.6 (0.7) | .31 | |
| - IC | 3.8 (0.9) | 3.6 (0.5) | .39 | |
| - VEO-IBD | 4.4 (0.4) | 3.8 (0.6) | .05* | |
| CRPb | Overall | 32.6 (40.8) | 44.0 (96.2) | .16 |
| - Crohns | 41.2 (44.1) | 55.3 (113.8) | .21 | |
| - UC | 30.4 (55.9) | 22.9 (38.7) | .30 | |
| - IC | 17.7 (27.9) | 29.2 (36.0) | .32 | |
| - VEO-IBD | 3.7 (4.1) | 5.4 (4.1) | .29 | |
| ESRb | Overall | 37.2 (28.9) | 36.0 (32.0) | .40 |
| - Crohn’s | 41.8 (30.6) | 39.2 (32.4) | .33 | |
| - UC | 32.3 (25.0) | 32.4 (34.4) | .50 | |
| - IC | 35.3 (41.2) | 23.0 (4.0) | .32 | |
| - VEO-IBD | 18.3 (8.3) | 17.8 (16.1) | .48 |
Abbreviations: CRP, C-reactive protein; ESR, sedimentation rate; IC, indeterminate colitis; UC, ulcerative colitis; VEO-IBD, very early onset inflammatory bowel disease.
bStatistical analysis for this variable performed with independent t-test.
*Denotes statistical significance at α ≤ .05.
| . | . | Pre-COVID (N = 107) . | During-COVID (N = 104) . | P-value . |
|---|---|---|---|---|
| Fecal calprotectinb | Overall | 867.1 (682.8) | 1653.5 (1677.4) | .001* |
| - Crohns | 650.5 (507.3) | 1692.5 (1854.7) | .003* | |
| - UC | 1153.9 (847.9) | 1691.8 (1338.4) | .09 | |
| - IC | 1214.7 (17.4) | 882.0 (18.4) | .001* | |
| - VEO-IBD | 1055.3 (867.7) | 1447.8 (1417.8) | .35 | |
| Hemoglobinb | Overall | 11.5 (1.8) | 11.1 (2.3) | .13 |
| - Crohns | 11.5 (1.5) | 11.1 (2.4) | .15 | |
| - UC | 11.5 (2.2) | 11.3 (2.3) | .37 | |
| - IC | 11.8 (2.7) | 10.8 (1.7) | .29 | |
| - VEO-IBD | 10.4 (0.9) | 11.1 (1.4) | .20 | |
| Albuminb | Overall | 3.5 (0.8) | 3.3 (0.8) | .08 |
| - Crohns | 3.4 (0.7) | 3.1 (0.9) | .06 | |
| - UC | 3.5 (0.9) | 3.6 (0.7) | .31 | |
| - IC | 3.8 (0.9) | 3.6 (0.5) | .39 | |
| - VEO-IBD | 4.4 (0.4) | 3.8 (0.6) | .05* | |
| CRPb | Overall | 32.6 (40.8) | 44.0 (96.2) | .16 |
| - Crohns | 41.2 (44.1) | 55.3 (113.8) | .21 | |
| - UC | 30.4 (55.9) | 22.9 (38.7) | .30 | |
| - IC | 17.7 (27.9) | 29.2 (36.0) | .32 | |
| - VEO-IBD | 3.7 (4.1) | 5.4 (4.1) | .29 | |
| ESRb | Overall | 37.2 (28.9) | 36.0 (32.0) | .40 |
| - Crohn’s | 41.8 (30.6) | 39.2 (32.4) | .33 | |
| - UC | 32.3 (25.0) | 32.4 (34.4) | .50 | |
| - IC | 35.3 (41.2) | 23.0 (4.0) | .32 | |
| - VEO-IBD | 18.3 (8.3) | 17.8 (16.1) | .48 |
| . | . | Pre-COVID (N = 107) . | During-COVID (N = 104) . | P-value . |
|---|---|---|---|---|
| Fecal calprotectinb | Overall | 867.1 (682.8) | 1653.5 (1677.4) | .001* |
| - Crohns | 650.5 (507.3) | 1692.5 (1854.7) | .003* | |
| - UC | 1153.9 (847.9) | 1691.8 (1338.4) | .09 | |
| - IC | 1214.7 (17.4) | 882.0 (18.4) | .001* | |
| - VEO-IBD | 1055.3 (867.7) | 1447.8 (1417.8) | .35 | |
| Hemoglobinb | Overall | 11.5 (1.8) | 11.1 (2.3) | .13 |
| - Crohns | 11.5 (1.5) | 11.1 (2.4) | .15 | |
| - UC | 11.5 (2.2) | 11.3 (2.3) | .37 | |
| - IC | 11.8 (2.7) | 10.8 (1.7) | .29 | |
| - VEO-IBD | 10.4 (0.9) | 11.1 (1.4) | .20 | |
| Albuminb | Overall | 3.5 (0.8) | 3.3 (0.8) | .08 |
| - Crohns | 3.4 (0.7) | 3.1 (0.9) | .06 | |
| - UC | 3.5 (0.9) | 3.6 (0.7) | .31 | |
| - IC | 3.8 (0.9) | 3.6 (0.5) | .39 | |
| - VEO-IBD | 4.4 (0.4) | 3.8 (0.6) | .05* | |
| CRPb | Overall | 32.6 (40.8) | 44.0 (96.2) | .16 |
| - Crohns | 41.2 (44.1) | 55.3 (113.8) | .21 | |
| - UC | 30.4 (55.9) | 22.9 (38.7) | .30 | |
| - IC | 17.7 (27.9) | 29.2 (36.0) | .32 | |
| - VEO-IBD | 3.7 (4.1) | 5.4 (4.1) | .29 | |
| ESRb | Overall | 37.2 (28.9) | 36.0 (32.0) | .40 |
| - Crohn’s | 41.8 (30.6) | 39.2 (32.4) | .33 | |
| - UC | 32.3 (25.0) | 32.4 (34.4) | .50 | |
| - IC | 35.3 (41.2) | 23.0 (4.0) | .32 | |
| - VEO-IBD | 18.3 (8.3) | 17.8 (16.1) | .48 |
Abbreviations: CRP, C-reactive protein; ESR, sedimentation rate; IC, indeterminate colitis; UC, ulcerative colitis; VEO-IBD, very early onset inflammatory bowel disease.
bStatistical analysis for this variable performed with independent t-test.
*Denotes statistical significance at α ≤ .05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
